ES2114522T3 - Peptidos amiloides. - Google Patents

Peptidos amiloides.

Info

Publication number
ES2114522T3
ES2114522T3 ES88303803T ES88303803T ES2114522T3 ES 2114522 T3 ES2114522 T3 ES 2114522T3 ES 88303803 T ES88303803 T ES 88303803T ES 88303803 T ES88303803 T ES 88303803T ES 2114522 T3 ES2114522 T3 ES 2114522T3
Authority
ES
Spain
Prior art keywords
amylin
kcntat
found
peptides
synthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88303803T
Other languages
English (en)
Inventor
Garth James Smith Cooper
Anthony Charles Willis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2114522T3 publication Critical patent/ES2114522T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA AMILINA SE HA ENCONTRADO UTIL PARA LA CONFIRMACION O PREDICCION DE DIABETES MELLITUS Y PARA SU EMPLEO EN EL TRATAMIENTO DE LA VASO DILATACION. EN PARTICULAR SE HA ENCONTRADO QUE LA SECUENCIA KCNTAT ES IMPORTANTE EN LA AMILINA Y SEPROPORCIONAN PEPTIDOS SINTETICOS QUE CONTIENEN SECUENCIAS QUE INCLUYEN LA KCNTAT. TAMBIEN SE PROPORCIONAN AMILINA SINTETICA, PEPTIDOS DEL TIPO DE LA AMILINA, UNA AMILINA SUSTANCIALMENTE PURA, VARIOS HEXAIENTOS PARA LA PREPARACION DE DAP INCLUYENDO UN VECTOR QUE CONTIENE UNA SECUENCIA GENETICA DE LA AMILINA.
ES88303803T 1987-04-27 1988-04-27 Peptidos amiloides. Expired - Lifetime ES2114522T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878709871A GB8709871D0 (en) 1987-04-27 1987-04-27 Peptides

Publications (1)

Publication Number Publication Date
ES2114522T3 true ES2114522T3 (es) 1998-06-01

Family

ID=10616392

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88303803T Expired - Lifetime ES2114522T3 (es) 1987-04-27 1988-04-27 Peptidos amiloides.

Country Status (9)

Country Link
EP (1) EP0289287B1 (es)
JP (3) JP2766647B2 (es)
AT (1) ATE162802T1 (es)
CA (1) CA1341333C (es)
DE (1) DE3856121T2 (es)
ES (1) ES2114522T3 (es)
GB (1) GB8709871D0 (es)
GR (1) GR3026640T3 (es)
HK (1) HK1003033A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454299B (sv) * 1986-10-08 1988-04-18 Westermark P Sats innehallande polypeptid som finns i pankreasoamyloid och/eller antikroppar riktade mot polypeptiden
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
AU631112B2 (en) * 1988-01-11 1992-11-19 Amylin Corporation Treatment of type 2 diabetes mellitus
US5405831A (en) * 1989-07-08 1995-04-11 Amylin Pharmaceuticals, Inc. Treatment of bone disorders
ES2080802T3 (es) * 1989-07-10 1996-02-16 Amylin Pharmaceuticals Inc Uso de un antagonista de amilina en la preparacion de un medicamento para el tratamiento de la obesidad e hipertension intrinseca y desordenes asociados.
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
EP0503827A1 (en) * 1991-03-15 1992-09-16 Pfizer Inc. Amylin and calcitonin gene-related peptide use and antagonists thereof
SG49239A1 (en) * 1991-05-24 1998-05-18 Amylin Pharmaceuticals Inc Amylin and possibly insulin containing composition for the treatment of aneroxia and related states
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
WO1993019774A1 (en) * 1992-04-03 1993-10-14 Amylin Pharmaceuticals, Inc. Amylin and possibly insulin containing composition for the treatment of anorexia and related states
NZ253449A (en) * 1992-05-15 1994-12-22 Amylin Pharmaceuticals Inc Monoclonal antibody binding to the c-terminal end of human amylin and kits and assays employing it
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
CZ69596A3 (en) 1993-09-07 1997-06-11 Amylin Pharmaceuticals Inc Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
ES2285707T3 (es) 1994-10-21 2007-11-16 Nps Pharmaceuticals, Inc. Compuestos activos frente al receptor de calcio.
WO1997026321A2 (en) * 1996-01-19 1997-07-24 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
WO1997041090A1 (en) 1996-05-01 1997-11-06 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
DE19725619A1 (de) * 1997-06-17 1998-12-24 Fraunhofer Ges Forschung Peptide als Agonisten und/oder Inhibitoren der Amyloidbildung und Zytotoxizität sowie der Verwendung bei Alzheimer'schen Krankheit, beim Typ II Diabetes mellitus und bei spongiformen Encephalopathien
US6821954B2 (en) * 1997-09-18 2004-11-23 Auckland Uniservices Limited Compounds and uses thereof in treating bone disorders
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
CA2422911A1 (en) * 2000-09-19 2002-03-28 Paul Fraser New inhibitors of iapp fibril formation and uses thereof
WO2004037168A2 (en) 2002-10-18 2004-05-06 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
ATE471340T1 (de) 2004-02-11 2010-07-15 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
WO2005079830A1 (en) * 2004-02-23 2005-09-01 Paul Fraser Inhibitors of amyloid fibril formation and uses thereof
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
WO2006010533A2 (en) * 2004-07-28 2006-02-02 F. Hoffmann-La Roche Ag Pancreatic polypeptide as target/marker of beta cell failure
CN101094689B (zh) 2004-11-01 2013-06-12 安米林药品有限责任公司 治疗肥胖以及肥胖相关疾病和病症的方法
CN102343084A (zh) 2005-03-31 2012-02-08 安米林药品公司 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂
EP1996224B1 (en) 2006-03-15 2012-11-07 Novo Nordisk A/S Mixtures of amylin and insulin
ES2550761T3 (es) * 2009-11-25 2015-11-12 Novo Nordisk A/S Método para producción de polipéptidos
CN103308670B (zh) 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
US9475866B2 (en) 2012-09-12 2016-10-25 Neurimmune Holding Ag Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereof
US9656017B2 (en) 2014-06-20 2017-05-23 Howard E. Greene Infusion delivery devices and methods
CN110467666A (zh) * 2019-09-17 2019-11-19 湖北强耀生物科技有限公司 一种新型胰岛淀粉样多肽的合成方法
TW202144387A (zh) * 2020-02-11 2021-12-01 美商聯合生物醫學公司 針對胰島澱粉樣多肽（iapp）的胜肽免疫原及其預防和治療與聚集iapp相關疾病的製劑
WO2025150507A1 (ja) * 2024-01-12 2025-07-17 学校法人東邦大学 インスリン・アミロイド化重合蛋白質、抗体、抗体産生ｂ細胞および医療用組成物
CN119930779A (zh) * 2025-02-10 2025-05-06 南京工业大学 采用淀粉样蛋白基序调节嵌合蛛丝蛋白亲疏水性的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE500044C2 (sv) * 1985-02-15 1994-03-28 Gambro Lundia Ab Peptidförening, antiserum framställt med användning av denna förening samt användning av föreningen
SE454299B (sv) * 1986-10-08 1988-04-18 Westermark P Sats innehallande polypeptid som finns i pankreasoamyloid och/eller antikroppar riktade mot polypeptiden
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus

Also Published As

Publication number Publication date
ATE162802T1 (de) 1998-02-15
CA1341333C (en) 2002-01-22
HK1003033A1 (en) 1998-09-30
JPH09133679A (ja) 1997-05-20
EP0289287A3 (en) 1990-05-30
JPH10168099A (ja) 1998-06-23
GR3026640T3 (en) 1998-07-31
JP2766647B2 (ja) 1998-06-18
EP0289287B1 (en) 1998-01-28
DE3856121T2 (de) 1998-07-23
EP0289287A2 (en) 1988-11-02
DE3856121D1 (de) 1998-03-05
GB8709871D0 (en) 1987-06-03
JPS6463594A (en) 1989-03-09

Similar Documents

Publication Publication Date Title
ATE162802T1 (de) Amyloid-peptide
EP0208491A3 (en) Hybrid polypeptides and process for their preparation
EG19101A (en) Process for preparing of expression of human proapolipoprotein A.1.
HUT46638A (en) Process for producing 1,1,1-trifluoro-2,2-dichloroethane in the presence of hydrogen fluoride catalyst
IL62553A0 (en) Vectors comprising dna sequences and methods for producing recombinant dna molecules and cloning vectors
HUT46356A (en) Process for producing the preprotein of apc polypeptide and the dna encoding it, as well as for the diagnostic utilization of the dna and the protein
DE3163867D1 (en) Novel substituted pyrazinyl-1,2,4-oxadiazol-5-ones, a process for preparing same and a pharmaceutical composition containing same
IL70414A (en) Polypeptide having human h2-relaxin activity,double-stranded dna fragments coding therefor,vectors containing the dna fragments and methods for preparing the polypeptide,dna fragments and vectors
HUT46061A (en) Dna sequences encoding hirudin-like protein and process for producing such proteins
HUT55801A (en) Process for producing anti-coagulative peptides marked with radioactivity
DE3885366D1 (de) Verfahren zur Herstellung von Pyrrolo-(3,4-c)pyrrolen.
ATE237689T1 (de) Dna kodierend für propylendopeptidase und dessen verwendung
PH23901A (en) Treatment of diabetes using fluoxetine
HUT47136A (en) Process for producing cyclic peptides with anticoagulant effect
DE3260830D1 (en) Process for the manufacture of globin or blood cell protein and heme from hemoglobin
DE3851364D1 (de) Verfahren zur Herstellung von supraleitendem Material.
ZA902054B (en) Production and use of anthelmintic agents and protective immunogens
HUT53125A (en) Process for producing peptides with anticoagulant activity
PT73587B (en) Process for preparing novel peptides
EP0281089A3 (en) Process for the preparation of factor viii:c deficient plasma, and deficient plasma obtained therwith
IL89877A0 (en) Process for the preparation of proteins which start with n-terminal proline
ZA832293B (en) Chromophoric peptides,a process for their preparation,agents containing them and their use for determining dd-carboxypeptidases
GB2220215B (en) Process for treating leather
DE3851214D1 (de) Verfahren zur Herstellung von flachen Vorrichtungen zum Pumpen von Sauerstoff.
IT1221857B (it) Per cinturini in pelle per orologi

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 289287

Country of ref document: ES